Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference81 articles.
1. Annual hazard rates of recurrence for breast cancer after primary therapy;Saphner;J Clin Oncol,1996
2. Distant metastasis: the most common type of early recurrence with adjuvant tamoxifen therapy;Doughty;Breast Cancer Res Treat,2007
3. Breast cancer relapse and related mortality in US patients with early breast cancer;Lamerato;J Clin Oncol,2005
4. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer;Howell;Lancet,2005
5. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer;Coombes;N Engl J Med,2004
Cited by 109 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Identifying determinants of adherence to adjuvant endocrine therapy following breast cancer: A systematic review of reviews;Cancer Medicine;2024-01-19
2. Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial;The Lancet;2022-11
3. The relationship among psychosocial adaptation, medication adherence and quality of life in breast cancer women with adjuvant endocrine therapy;BMC Women's Health;2022-04-27
4. Treatment and Survivorship Interventions to Prevent Poor Body Image Outcomes in Breast Cancer Survivors;Breast Cancer: Targets and Therapy;2021-12
5. Assessing Predictors of Tamoxifen Nonadherence in Patients with Early Breast Cancer;Patient Preference and Adherence;2021-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3